Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GDC-7035 in KRAS G12D-mutated advanced or metastatic solid tumors
NL-OMON61611Phase 2Recruiting
- Sponsor
- Genentech
- Start
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of GDC-7035 in Nonhematologic neoplasms (2 arms), sponsored by Genentech. Primary endpoints: Incidence and severity of adverse events, Dose-limiting toxicities and 3 more. Started Aug 2026; status: recruiting.
02
Drugs
GDC-7035
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on NL-OMON61611.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61611.